| 36 | Rapid Accumulation
and Internalization of Radiolabeled HerceptinTM in a Inflammatory
Breast Cancer Xenograft with Vasculogenic Mimicry Predicted
by the Contrast-Enhanced Dynamic MRI with the Macromolecular
Contrast Agent G6- (1B4M-Gd)256 Kobayashi, Hisataka¹ ; Shirakawa, Kazuo³ ; Kawamoto, Satomi¹ ; Saga, Tsuneo² ; Hiraga, Akira² ; Togashi, Kaori¹ ; Konishi, Junji² ; Brechbiel, Martin4; Wakasugi, Hiro³ ¹Department of Diagn. Intervent. Imagiology, Kyoto University, Kyoto, Japan; ²Department of Nuclear Medicine and Diagn. Imaging, Kyoto University, Kyoto, Japan; ³Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan; 4Radiation Oncology Branch, National Cancer Institute, Bethesda, MD |
| 37 | Effects of transforming
growth factor - ß on the ability of dendritic cells to
stimulate an anti-tumor response Kobie JJ, Akporiaye ET Department of Microbiology and Immunology, University of Arizona, Tucson, AZ |
| 38 | Enhancement of NK-mediated
anti-tumor effects against allogeneic tumor by inhibitory receptor
blockade Koh, Crystal¹ Blazar, Bruce² Bennett, Michael³ Murphy, William4 ¹Laboratory of Molecular Immunoregulation, National Cancer Institute – Frederick, Frederick, MD; ²Dept of Pediatrics, Div of BMT, University of Minnesota Cancer Center, Minneapolis, MN; ³Dept of Pathology, Univ of Texas Southwestern Medical Center Dallas, TX; 4IRSP, SAIC – Frederick, Frederick, MD |
| 39 | Reactivity of anti-Her-2/neu
CTL against modified Her-2/neu peptides Lake DF, Dionne SO, Smith, MH Cancer Center, University of Arizona, Tucson, AZ |
| 40 | Vaccination of a prostate cancer
patient with the candidate cancer vaccine IGN101: A case study Samonigg H1, Hofmann G¹, Gusel S¹, Hopfner M², Putz T², Himmler G², Loibner H² ¹Dept. Oncol. University Hospital, Graz; Austria; ²igeneon AG, Vienna; Austria |
| 41 | Enhancing antitumor
(anti-oncotope) antibody (IgM) promotes tumor growth in the
syngeneic host Manson, LA, Snyder, AK Dept. Biology, University of Pennsylvania, Philadelphia, PA |
| 42 | Evaluation of the interleukin-2
selective agonist BAY-50-4798 in patients with advance melanoma
and renal cell carcinoma, a Cytokine Working Group-coordinated
phase I study Margolin, K¹ Atkins, M B² Weber, J³ Dutcher, JP4; Ernstoff, M5; Smith, J6; Clark, J7; O’Day, S8; Flaherty, L9; Baar, J10; Sosman, J11; Thompson, JA12; Smith, J13; Lathia, C13; Martell, RE13 ¹City of Hope, Duarte, CA; ²Beth Israel Deaconess, Boston, MA; ³USC, Los Angeles, CA ; 4Our Lady of Mercy, Bronx, NY; 5Dartmouth Lebanon, NH; 6Providence, Portland, OR; 7Loyola Maywood, IL; 8John Wayne, Santa Monica, CA; 9Wayne State Detroit, MI; 10U Pittsburgh, Pittsburgh, PA; 11U Illinois, Chicago, IL; 12U Washington, Seattle, WA; 13Bayer Pharmaceuticals West Haven, CT |
| 43 | Modulation of anti-tumor responses
in mice by Albuleukin, an Interleukin-2 / human serum albumin
fusion protein Melder RJ, Grzegorzewski K, Osborn B, Riccobene T, Beebe L, Wei P, Zhang G, Chen G, Stolow D, Migone T, Kanakaraj P, Ruben S. Human Genome Sciences, Rockville, MD |
| 44 | Endogenous Immune Responses Control
Minimal Residual Neoplastic Disease in Murine Osteosarcoma Fraia Melchionda, Manoj Sinha, Chand Khanna, Melinda Merchant, Terry Fry, Lee Helman and Crystal Mackall Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD |
| 45 | Oral (1→3),
(1→4) →D-glucan synergizes with the antiganglioside
GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma Modak, Shakeel; Cheung, Nai-Kong Pediatrics, Memorial Sloan-Kettering Cancer Center |
| 46 | Efficiency of Adenoviral
Mediated Gene Transfer into Murine Bone Marrow-Derived Dendritic
Cells Morrison B, Sakai Y, Janik JE, van den Broeke L, Berzofsky JA, Morris JC Metabolism Branch, Center for Cancer Research, NCI, Bethesda, MD |
